We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 1.37% | 18.50 | 18.00 | 19.00 | 18.50 | 18.25 | 18.25 | 123,034 | 08:41:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.51 | 16.87M |
TIDMOPTI
RNS Number : 3061K
OptiBiotix Health PLC
01 September 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
PDMR Dealing
Notification and public disclosure of a transaction by a person discharging managerial responsibilities (PDMR).
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that it received notification on 31 August 2021 that René Kamminga (CEO, Optibiotix Ltd), acquired 8,188 ordinary shares in the Company on 31 August 2021 at a price of 55.4 pence per share.
Following the transaction, Mr Kamminga is interested in 43,188 ordinary shares in the Company, representing 0.05% of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com Neil Davidson, Chairman Contact via Walbrook below Stephen O'Hara, Chief Executive Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880 Liam Murray / Jo Turner / Ludovico Lazzaretti Cenkos Securities plc (Broker) Tel: 020 7397 8900 Callum Davidson / Neil McDonald Michael Johnson / Russell Kerr (Sales) Walbrook PR Ltd Mob: 07876 741 001 Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ------------------------------------------------------------------------------------------ a. Name René Kamminga ---------------------------------------- ------------------------------------------------ 2 Reason for notification ---------------------------------------- ------------------------------------------------ a. Position/Status PDMR ---------------------------------------- ------------------------------------------------ b. Initial notification/ Initial Notification Amendment ---------------------------------------- ------------------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------------------ a. Name OptiBiotix Health Plc ---------------------------------------- ------------------------------------------------ b. LEI 213800UKYQFT941QHS14 ---------------------------------------- ------------------------------------------------ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------------------ a. Description of 8,188 ordinary shares of 2p each the financial instrument, type of instrument ISIN: GB00BP0RTP38 Identification Code ---------------------------------------- ------------------------------------------------ b. Nature of the Purchase of 8,188 ordinary shares in the transaction Company ---------------------------------------- ------------------------------------------------ c. Price(s) and volume(s) Price(s) per Volume(s) share ---------------------------------------- ------------------------- 55.4p 8,188 ------------------------- ---------------- d. Aggregated information * Volume n/a * Price ---------------------------------------- ------------------------------------------------ e. Date of the transaction 31 August 2021 ---------------------------------------- ------------------------------------------------ f. Place of the transaction London Stock Exchange, AIM ---------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSDUEFFEFSESA
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
1 Year Optibiotix Health Chart |
1 Month Optibiotix Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions